Clinical Guidelines: Dosing and Switching Strategies for Long-Acting Risperidone

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 16, 2003, Pages 41-46

  Marder, Stephen R ^a   Conley, Robert ^b   Ereshefsky, Larry ^c   Kane, John M ^d,e   Turner, Martin S ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e ZUCKER HILLSIDE HOSPITAL   (United States)

^f STOBHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; PROPRANOLOL; RISPERIDONE;

ANXIETY DISORDER; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INJECTION; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SWEATING; SYMPTOM; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAMUSCULAR; PRACTICE GUIDELINES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0346996937     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (4)

1. Kane JM, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132
2. Ereshefsky L, Mascarenas CA. Comparisons of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003;64(suppl 16):18-23
3. Lasser RA, Ramstack JM, Grandolfi GP, et al. Long-acting injectable risperidone (Risperdal Consta): manufacture using Medisorb microsphere technology, pharmacokinetics, and injection-site assessments. Presented at the 155th annual meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa
4. Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry 2003;64(suppl 16):34-40